Skip to main content

Novo Holdings — Portfolio, Page 9

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

216
Companies
$15.2B
Total invested
$84.4M
Avg. check
19
Industries
Biotechnology 19Health Care 12Medical 12Pharmaceutical 12Therapeutics 9Biopharma 5+13 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 193216 of 216
BIOMILQ
October 2021

Unlocking human potential with breakthrough mammary biotechnology.

AgTech · Durham$21.0M Series A
Tarveda Therapeutics
September 2021

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors.

Biotechnology · Watertown$6.0M Series Unknown
Aristea Therapeutics
July 2021

Aristea Therapeutics is a developer of novel therapies created for autoimmune diseases.

Biotechnology · San Diego$63.0M Series B
NeRRe Therapeutics
July 2021

NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.

Biotechnology · Stevenage$27.6M Series B
Bolt Biotherapeutics
June 2021

Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy.

Biotechnology · Redwood City$15.0M Post Ipo Equity
Hummingbird Bioscience
May 2021

Hummingbird Bioscience focuses on the discovery and early development of oncology drugs.

Biotechnology · Woodlands$125.0M Series C
Entasis Therapeutics
May 2021

Entasis Therapeutics is developing a portfolio of innovative cures.

Biotechnology · Waltham$7.5M Post Ipo Equity
BioPhero
March 2021

BioPhero is a pioneer in providing low-cost bio-based pheromones for pest management.

Chemical · Lyngby$16.8M Series A
ZELP
March 2021

ZELP aims to significantly reduce the environmental impact of the livestock industry.

Environmental Engineering · London$10.0M Series A
Cyteir Therapeutics
February 2021

Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.

Biopharma · Cambridge$80.0M Series C
Stargazer Pharmaceuticals
November 2020

Stargazer Pharmaceuticals offers the therapy of standards disorder and manufacturer of pharmaceuticals products.

Manufacturing · Boston$57.0M Series A
Syndesi Therapeutics
September 2020

Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions.

Biotechnology · Louvain-la-neuve$7.0M Series A
ReViral
August 2020

ReViral is a biotechnology company that develops and offers antiviral therapies for patients.

Biotechnology · Stevenage$44.0M Series C
NBE-Therapeutics
January 2020

NBE-Therapeutics is a biotech company that develops oncology treatments for cancer patients.

Biotechnology · Basel$22.0M Series C
STipe Therapeutics
September 2019

STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.

Biotechnology · Aarhus$21.8M Series A
Forendo Pharma
July 2019

Forendo Pharma is a developer of novel drugs intended for the treatment of urological and other endocrinological diseases.

Health Care · Turku$5.6M Series Unknown
AFYX Therapeutics
June 2019

AFYX Therapeutics is a clinical stage biopharmaceutical company

Biotechnology · Copenhagen$13.0M Debt Financing
Therachon
August 2018

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases

Biotechnology · Basel$60.0M Series B
Rainier Therapeutics
May 2018

Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.

Biopharma · San Leandro$20.0M Series B
Outpost Medicine
November 2017

Outpost Medicine is a biopharmaceutical company

Biopharma · Indianapolis$20.0M Series A
Genoa Pharmaceuticals
May 2017

Genoa Pharmaceuticals develops therapies for the treatment of idiopathic pulmonary fibrosis.

Biopharma · San Diego$62.0M Series A
Amra
January 2017

Amra uses cloud-based, computer aided service to analytically transform MR images into body composition measurements.

Health Care · Linköping$8.9M Series Unknown
Macrophage Pharma
January 2017

Macrophage Pharma is a immune-oncology company

Biotechnology · Englewood Cliffs$11.0M Series A
Glionova
December 2014

Glionova is a privately held biopharmaceutical company focused on developing new therapies for cancer.

Biopharma · Stockholm$5.7M Series A

Where Novo Holdings invests

Biotechnology19
Health Care12
Medical12
Pharmaceutical12
Therapeutics9
Biopharma5

About Novo Holdings's portfolio

How many companies has Novo Holdings invested in?

Novo Holdings has invested in 216 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Novo Holdings invest in?

Novo Holdings's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics. The firm invests across 19 different industry categories.

What is Novo Holdings's largest investment?

Among tracked funding rounds, Hummingbird Bioscience received $125.0M in a Series C round. Novo Holdings's total known invested capital is $15.2B.

What is the average investment size for Novo Holdings?

Novo Holdings's average investment size is $84.4M across its portfolio of 216 companies.

What are Novo Holdings's most recent investments?

Recent Novo Holdings portfolio additions include BIOMILQ, Tarveda Therapeutics, Aristea Therapeutics, NeRRe Therapeutics, Bolt Biotherapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 216 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →